Europe Liquid Biopsy Market Outlook and Strategic Insights by 2027

Europe, the liquid biopsy market, is anticipated to reach US$ 2,251.12 Mn in 2027 from US$ 1,097.82 Mn in 2019. The market is projected to grow with a CAGR of 9.5% from 2020-2027.

The liquid biopsy market is growing primarily due to government and global health organizations initiatives. Restraining factor such as, low sensitivity of liquid biopsy is likely to damage the growth of the market in the coming years. On the other hand, rising liquid biopsy due to growing application and advancements is expected to have a positive impact on the growth of the Europe liquid biopsy market in the coming years.

Since 2014, the clinical use of liquid biopsy has significantly increased. Several assays were commercially available and FDA-approved. For instance, in 2016, Cobas EGFR Mutation Test v2 was FDA approved to determine the eligibility of non-small cell lung cancer patients to receive specific EGFR tyrosine kinase inhibitors. Though its adoption in clinics is slower due to false-negative concerns, its clinical utilization is increasing, which is driven by patients and physicians demand to identify targetable mutations for off-label use or clinical trial enrolment. The application of liquid biopsy is expanding, and the emerging methods include mutational profiling, assessing treatment response, residual disease monitoring, exposure of disease recurrence, and monitoring for the emergence of resistance mutations. The uses of liquid biopsy range from monitoring cancer growth to detecting genetic mutations, identifying signs of relapse, and predicting sensitivity to immunotherapy.

The advantages of liquid biopsies and technological improvements will continue to expand their applicability and utility in monitoring patients for relapse and determining the best treatments. The growing applications are likely to offer significant opportunity for the growth of the market.

Moreover, in the United States, due to an increasing number of infected patients, healthcare professionals and leading organizations are distracting the flow of healthcare resources from research & development to primary care, which is slowing down the process of innovation. Furthermore, the pandemic spread is also preventing the clinical trials, drug development, and diagnostic industry in the US. For instance, California-based Lucence Diagnostics Pte Ltd., who develops liquid biopsy and has a known player in this industry, has been diverted now to manufacture kits for COVID-19.

In 2019, the Germany accounted for the largest market share in Europe liquid biopsy market, and it is also expected to grow at a faster pace over the forecast period. Increasing number of cancer cases, and presence of major market players in the Germany are responsible for the highest revenue share of the region. Moreover, increasing government initiatives help to grow the market in the forecast period. Hence, considering the mentioned factors, the liquid biopsy market is expected to grow at a significant pace in the Germany during the forecast period.

Rest of Europe Liquid Biopsy Market Revenue and Forecasts to 2027 (US$ Mn)

EUROPE LIQUID BIOPSY – MARKET SEGMENTATION

By Product & Service

• Equipment
• Reagents & Kits
• Services

By Sample

• Blood Based
• Urine Based
• Other samples

By Circulating Biomarker

• Circulating Tumor Cells (CTC)
• Exosomes
• Free Nucleic Acid

By Application

• Noninvasive Prenatal Testing (NIPT)
• Oncology
• Transplant Diagnostics
• Other Applications

By End User

• Academic & Research Institutes
• Hospitals
• Reference Laboratories
• Other End Users

By Geography

• Europe

• • UK
  • Germany
  • France
  • Italy
  • Spain

Company Profiles

• F. Hoffmann-la Roche ltd
• Inivata Ltd
• LungLife AI, Inc.
• Exosome Diagnostics
• MDxHealth

Europe Liquid Biopsy Report Scope